Anadys reiterated by JMP at strong buy

Anadys Pharmaceuticals Inc. was reiterated by JMP Securities analyst Adam Cutler at a strong buy rating and price target of $17 per share following second-quarter results. Anadys shares Wednesday were down $0.16, or 1.33%, at $11.87 on volume of 204,341 shares versus the three-month running average of 191,862 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.